India Expands Schedule H2 Drug Regulations

Health Ministry Notification on Schedule H2 Drugs

1. Expansion of Schedule H2:

   • Schedule H2, introduced in 2022-23, has been expanded to include entire therapeutic classes instead of a curated list of brands.
   • This shift represents a move from revenue-based regulation to risk-based regulation.

2. Regulatory Framework:

   • The framework aims to address active pharmaceutical ingredient regulation and export-oriented compliance.
   • Each drug pack is now required to include a barcode or QR code for authenticity verification, which encodes product identifiers, manufacturing license numbers, and batch numbers.

3. Counterfeit Drug Concerns:

   • WHO has reported a significant influx of counterfeit antimicrobials in low- and middle-income countries.
   • India faces one of the highest rates of antimicrobial resistance globally, exacerbated by substandard drugs.

4. Impact on Public Health:

   • The introduction of more detailed tracking is aimed at mitigating risks associated with counterfeit drugs, which have affected vaccines, cancer treatments, and antimicrobials.
   • The U.S. Trade Representative has identified India as a leading source of counterfeit medicines, with a substantial number of seizures occurring at the U.S. border linked to India.

5. Jan Vishwas Act 2026:

   • Policy changes under the Jan Vishwas Act delineate procedural and substantial non-compliance, impacting enforcement strategies.

6. Implementation Challenges:

   • Effective QR code use requires a state-managed database for real-time access by pharmacists and regulators.
   • There is a need for interoperable software and scanning infrastructure across states.

7. Awareness and Verification:

   • Emphasis on developing a consumer habit of verifying medicines before purchase is critical for the effectiveness of the new system.

8. Impact on MSMEs:

   • New compliance requirements may place a burden on MSME manufacturers, necessitating support to adapt to these changes.

9. Digital Governance Considerations:

   • Sensitive prescription data related to controlled substances must be managed within a digital governance framework that is yet to be established.

10. Outlook:

    • The success of the new framework hinges on robust implementation strategies rather than just regulatory announcements. Improvements in industry reputation depend on how effectively these measures are put into practice.

This summary encapsulates the major updates regarding the expansion of Schedule H2 and its intended impact on drug regulation in India, providing key information for exam preparation.